Synovial Sarcoma of the Nerve-Clinical and Pathological Features: Case Series and Systematic Review.
Intraneural
Peripheral nerve
Plexus
SSPN
Synovial sarcoma
Journal
Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914
Informations de publication
Date de publication:
01 12 2019
01 12 2019
Historique:
received:
22
01
2019
accepted:
18
05
2019
pubmed:
23
8
2019
medline:
17
4
2020
entrez:
23
8
2019
Statut:
ppublish
Résumé
Synovial sarcoma of the nerve is a rare entity with several cases and case series reported in the literature. Despite an improved understanding of the biology, the clinical course is difficult to predict. To compile a series of patients with synovial sarcoma of the peripheral nerve (SSPN) and assess clinical and pathological factors and their contribution to survival and recurrence. Cases from 2 institutions collected in patients undergoing surgical intervention for SSPN. Systematic review including PubMed and Scopus databases were searched for related articles published from 1970 to December 2018. Eligibility criteria: (1) case reports or case series reporting on SSPN, (2) clinical course and/or pathological features of the tumor reported, and (3) articles published in English. From patients treated at our institutions (13) the average follow-up period was 3.2 yr. Tumor recurrence was seen in 4 cases and death in 3. Systematic review of the literature yielded 44 additional cases with an average follow-up period of 3.6 yr. From pooled data, there were 10 recurrences and 7 deaths (20% and 14%, respectively). Adjuvant treatment used in 62.5% of cases. Immunohistochemical markers used in diagnosis varied widely; the most common are the following: Epithelial membrane antigen (EMA), cytokeratin, vimentin, cluster of differentiation (CD34), and transducin-like enhancer of split 1 (TLE1). Statistical analysis illustrated tumor size and use of chemotherapy to be negative predictors of survival. No other factors, clinically or from pathologist review, were correlated with recurrence or survival. By combining cases from our institution with historical data and performing statistical analysis we show correlation between tumor size and death.
Sections du résumé
BACKGROUND
Synovial sarcoma of the nerve is a rare entity with several cases and case series reported in the literature. Despite an improved understanding of the biology, the clinical course is difficult to predict.
OBJECTIVE
To compile a series of patients with synovial sarcoma of the peripheral nerve (SSPN) and assess clinical and pathological factors and their contribution to survival and recurrence.
METHODS
Cases from 2 institutions collected in patients undergoing surgical intervention for SSPN. Systematic review including PubMed and Scopus databases were searched for related articles published from 1970 to December 2018. Eligibility criteria: (1) case reports or case series reporting on SSPN, (2) clinical course and/or pathological features of the tumor reported, and (3) articles published in English.
RESULTS
From patients treated at our institutions (13) the average follow-up period was 3.2 yr. Tumor recurrence was seen in 4 cases and death in 3. Systematic review of the literature yielded 44 additional cases with an average follow-up period of 3.6 yr. From pooled data, there were 10 recurrences and 7 deaths (20% and 14%, respectively). Adjuvant treatment used in 62.5% of cases. Immunohistochemical markers used in diagnosis varied widely; the most common are the following: Epithelial membrane antigen (EMA), cytokeratin, vimentin, cluster of differentiation (CD34), and transducin-like enhancer of split 1 (TLE1). Statistical analysis illustrated tumor size and use of chemotherapy to be negative predictors of survival. No other factors, clinically or from pathologist review, were correlated with recurrence or survival.
CONCLUSION
By combining cases from our institution with historical data and performing statistical analysis we show correlation between tumor size and death.
Identifiants
pubmed: 31435657
pii: 5552764
doi: 10.1093/neuros/nyz321
pmc: PMC6891799
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
E975-E991Informations de copyright
Copyright © 2019 by the Congress of Neurological Surgeons.
Références
J Neurosurg Pediatr. 2013 Apr;11(4):473-7
pubmed: 23414131
Front Oncol. 2014 Nov 17;4:324
pubmed: 25452937
Cancer. 1980 Apr 15;45(8):2109-18
pubmed: 6245788
Am J Surg Pathol. 1999 Jan;23(1):106-12
pubmed: 9888710
Hum Pathol. 1986 Oct;17(10):996-1008
pubmed: 2428727
J Hand Surg Br. 1985 Jun;10(2):243-4
pubmed: 2993455
Anticancer Res. 2014 Feb;34(2):777-83
pubmed: 24511012
Mod Pathol. 1996 Jul;9(7):738-41
pubmed: 8832556
Skeletal Radiol. 2017 Nov;46(11):1463-1468
pubmed: 28689338
World J Surg Oncol. 2006 Aug 22;4:55
pubmed: 16923196
Mod Pathol. 2004 Feb;17(2):258-63
pubmed: 14685256
Proc Natl Acad Sci U S A. 1987 Apr;84(7):1981-5
pubmed: 3031659
Ann Surg. 2009 Jun;249(6):1014-22
pubmed: 19474676
Cancer. 2006 Sep 1;107(5):1065-74
pubmed: 16881077
J Chemother. 2010 Dec;22(6):413-8
pubmed: 21303750
Plast Reconstr Surg. 1989 Mar;83(3):528-32
pubmed: 2537498
J Clin Oncol. 1998 Jan;16(1):197-203
pubmed: 9440743
Cancer. 1990 Sep 15;66(6):1253-65
pubmed: 2119249
Curr Treat Options Oncol. 2015 Mar;16(3):328
pubmed: 25777573
Ann Surg Oncol. 2007 Feb;14(2):597-604
pubmed: 17103076
Cancer. 1986 May 15;57(10):2006-21
pubmed: 3082508
Pathol Res Pract. 1994 Feb;190(2):168-77
pubmed: 7520165
Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):351-60
pubmed: 9788415
Turk Patoloji Derg. 2012;28(3):266-9
pubmed: 23011830
Ann Intern Med. 2009 Aug 18;151(4):W65-94
pubmed: 19622512
Rare Tumors. 2018 May 24;10:2036361318776495
pubmed: 29854355
Onkologie. 2009 Sep;32(8-9):503-5
pubmed: 19745595
Sarcoma. 2009;2009:756395
pubmed: 19360115
Cancer Genet Cytogenet. 1986 Sep;23(1):93
pubmed: 3017544
Cancer. 2004 Nov 15;101(10):2270-5
pubmed: 15484214
J Med Case Rep. 2018 Nov 9;12(1):334
pubmed: 30409199
Ann Oncol. 2011 Jan;22(1):207-14
pubmed: 20656792
Cancer Genet Cytogenet. 2002 Oct 15;138(2):153-6
pubmed: 12505262
Hum Pathol. 2011 Apr;42(4):568-77
pubmed: 21295819
Neurol Med Chir (Tokyo). 2008 Feb;48(2):77-82
pubmed: 18296877
Cancer. 2004 Aug 1;101(3):627-34
pubmed: 15274077
J Clin Pathol. 2008 May;61(5):672-6
pubmed: 18441160
J Surg Oncol. 2014 Dec;110(7):813-6
pubmed: 25111615
Am J Surg Pathol. 2017 Aug;41(8):1087-1096
pubmed: 28498283
Surg Oncol Clin N Am. 2016 Oct;25(4):789-802
pubmed: 27591499
Cancer Res. 2002 Mar 1;62(5):1573-7
pubmed: 11894862
Am J Pathol. 1984 Oct;117(1):18-25
pubmed: 6207733
Neurol India. 2011 Sep-Oct;59(5):783-5
pubmed: 22019681
Indian J Surg Oncol. 2011 Mar;2(1):24-6
pubmed: 22693395
Neurosurgery. 2012 May;70(5):1329-33; discussion 1333
pubmed: 21778914
J Hand Surg Asian Pac Vol. 2016 Oct;21(3):399-404
pubmed: 27595961
Clin Neurol Neurosurg. 1996 Aug;98(3):249-52
pubmed: 8884099
Skeletal Radiol. 1997 Nov;26(11):677-81
pubmed: 9428079
Rare Tumors. 2010 Jun 30;2(2):e32
pubmed: 21139834
JBJS Case Connect. 2014 May 28;4(2):e40-e6
pubmed: 29252495
Lab Invest. 1983 Apr;48(4):372-94
pubmed: 6187996
N Engl J Med. 2005 Aug 18;353(7):701-11
pubmed: 16107623
Neurosurgery. 2010 Apr;66(4):833-40
pubmed: 20190660
World J Surg Oncol. 2018 Aug 13;16(1):166
pubmed: 30103752
Mod Pathol. 2009 Jul;22(7):872-8
pubmed: 19363472
J Hand Surg Br. 1999 Jun;24(3):373-5
pubmed: 10433461
Arch Pathol Lab Med. 2000 Jun;124(6):864-7
pubmed: 10835522
Pediatr Neurosurg. 2007;43(5):382-5
pubmed: 17786003
Spine (Phila Pa 1976). 2001 Feb 1;26(3):310-3
pubmed: 11224869
Lancet Oncol. 2014 Apr;15(4):415-23
pubmed: 24618336